<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00949065</url>
  </required_header>
  <id_info>
    <org_study_id>2007-007794-23</org_study_id>
    <nct_id>NCT00949065</nct_id>
  </id_info>
  <brief_title>Intravenous Immunoglobulins in Complex-regional Pain Syndrome</brief_title>
  <acronym>PAINLESS</acronym>
  <official_title>Prospective, Double-blind, Randomised, Placebo-controlled, Cross-over Study to Investigate the Effect of Intravenous Immunoglobulins on Complex Regional Pain Syndrome (CRPS, M. Sudeck)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Giessen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether intravenous immunoglobulins are effective
      in the treatment of complex-regional pain syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CRPS, a chronic pain syndrome associated with trophic disturbances is a frequent complication
      after limb trauma. More than one third of the CRPS will continue to chronic disease including
      loss of function in one limb. Some reports implicate an autoimmune pathogenesis of CRPS.
      Especially the finding of autoantibodies against peripheral neurons and successful treatment
      in single cases provide evidence for a possible successful treatment of CRPS with intravenous
      immunoglobulins (IvIg). Therefore IvIg may be an important anti-inflammatory treatment to
      prevent severe chronification of CRPS. Since IvIg is mainly effective in B-cell-mediated
      autoimmune diseases, autoantibodies against autonomic neurons and the concentration of B-cell
      activating factors BAFF and APRIL will be measured in the course of the study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">April 2011</completion_date>
  <primary_completion_date type="Anticipated">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in impairment Level SumScore (ISS)</measure>
    <time_frame>after 0,3,6,9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain disability score</measure>
    <time_frame>0,3,6,9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (SF-36)</measure>
    <time_frame>0,3,6,9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titer of surface-binding neuronal autoantibodies in the serum</measure>
    <time_frame>0,3,6,9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of B-cell activating factors BAFF, APRIL</measure>
    <time_frame>0,3,6,9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Complex Regional Pain Syndrome Type 1</condition>
  <arm_group>
    <arm_group_label>Intravenous immunoglobulins (IvIg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 x 0.36-0.44g/Kg IvIg every 4 weeks, then 3 months washing out, then 3x NaCl 0.9% every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NaCl 0.9%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NaCl 0.9%, 3x, every 4 weeks, then 3 months washing out, then 0.36-0.44g/Kg IvIg, 3x, every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>intravenous immunoglobulins</intervention_name>
    <description>0.36-0.44g/Kg IvIg intravenous, 3x, every 4 weeks</description>
    <arm_group_label>Intravenous immunoglobulins (IvIg)</arm_group_label>
    <arm_group_label>NaCl 0.9%</arm_group_label>
    <other_name>Gamunex 10%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CRPS 1 (according to the IASP criteria) between 6 weeks and 6 months after diagnosis

          -  skin temperature of the affected side equal or higher than on non-affected side

          -  no change of the analgetic or co-analgetic medication within the last 10 days

        Exclusion Criteria:

          -  Immunosuppressive or immunomodulatory treatment within the last three months

          -  CRPS previously treated with sympathetic block, lidocaine patch, local DMSO, spinal
             cord stimulation, intrathecal drug administration

          -  Known immune-mediated neuropathy (CIDP, MMN, MADSAM)

          -  Selective IgA-deficiency

          -  Severe heart disease

          -  Tumour disease in the last 5 years

          -  Allergy against Gamunex 10%

          -  Chronic renal disease Vaccination with live vaccine within the last three months

          -  Member of another clinical trial within the last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Franz Blaes, MD</last_name>
    <phone>+49-641-99(0)</phone>
    <phone_ext>45357</phone_ext>
    <email>franz.blaes@neuro.med.uni-giessen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marlene Tschernatsch, MD</last_name>
    <phone>+49-641-99(0)</phone>
    <phone_ext>45400</phone_ext>
    <email>marlene.tschernatsch@neuro.med.uni-giessen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital of the Justus-Liebig-University</name>
      <address>
        <city>Giessen</city>
        <state>Hessen</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marlene Tschernatsch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Kohr D, Tschernatsch M, Schmitz K, Singh P, Kaps M, Schäfer KH, Diener M, Mathies J, Matz O, Kummer W, Maihöfner C, Fritz T, Birklein F, Blaes F. Autoantibodies in complex regional pain syndrome bind to a differentiation-dependent neuronal surface autoantigen. Pain. 2009 Jun;143(3):246-51. doi: 10.1016/j.pain.2009.03.009. Epub 2009 Apr 16.</citation>
    <PMID>19375222</PMID>
  </reference>
  <reference>
    <citation>Goebel A, Stock M, Deacon R, Sprotte G, Vincent A. Intravenous immunoglobulin response and evidence for pathogenic antibodies in a case of complex regional pain syndrome 1. Ann Neurol. 2005 Mar;57(3):463-4.</citation>
    <PMID>15732112</PMID>
  </reference>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2009</study_first_submitted>
  <study_first_submitted_qc>July 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2009</study_first_posted>
  <last_update_submitted>July 29, 2009</last_update_submitted>
  <last_update_submitted_qc>July 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>Franz Blaes, MD</name_title>
    <organization>Dept. of Neurology, Justus-Liebig-University, Am Steg 14, 35392 Giessen, Germany</organization>
  </responsible_party>
  <keyword>complex regional pain syndrome</keyword>
  <keyword>sympathetic reflex dystrophy</keyword>
  <keyword>intravenous immunoglobulins</keyword>
  <keyword>autoimmune disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Somatoform Disorders</mesh_term>
    <mesh_term>Complex Regional Pain Syndromes</mesh_term>
    <mesh_term>Reflex Sympathetic Dystrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

